Quantitative analysis for Structure Therapeutics Inc. (GPCR) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Sell (40.0) (grade D). Gem alpha score: 65.0. 31 signals analyzed (26 differentiated alt-data).
GPCR stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-30 | $42.17 | $40.81 | $41.45 |
| 2026-05-12 | $38.90 | $37.43 | $37.84 |
| 2026-05-22 | $40.38 | $38.70 | $39.19 |
| 2026-06-04 | $39.71 | $37.90 | $39.06 |
| 2026-06-16 | $43.09 | $41.71 | $42.91 |
| 2026-06-29 | $51.86 | $49.10 | $51.69 |
| 2026-07-10 | $54.99 | $52.44 | $53.36 |
| 2026-07-22 | $50.47 | $48.80 | $50.41 |
| 2026-08-03 | $48.71 | $46.58 | $48.36 |
| 2026-08-13 | $55.00 | $52.57 | $54.70 |
| 2026-08-25 | $51.02 | $49.37 | $49.92 |
| 2026-09-04 | $48.06 | $46.73 | $47.34 |
How Structure Therapeutics Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| ZLAB | Zai Lab Limited | $2.1B | 35.0 |
| ESTA | Establishment Labs Holdings Inc. | $2.1B | — |
| BHC | Bausch Health Companies Inc. | $2.1B | 33.0 |
| PHVS | Pharvaris N.V. | $1.9B | 72.0 |
View all Health Care stocks by valuation and signals →
Structure Therapeutics Inc. (GPCR) scores Sell (40.0), and the composite conceals a 72-point disagreement between its dimensions. It is strongest on analyst consensus at 90 and earnings quality at 82, and weakest on ML forecast at 22 and technicals at 18. A stock can carry analyst consensus that high while technicals sits at 18; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| analyst consensus | 90 |
| earnings quality | 82 |
| competitive moat | 81 |
| valuation | 72 |
| AI Alpha (gem) | 55 |
| ML forecast | 22 |
| technicals | 18 |
StoQuant analyzes 31 signals (26 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Structure Therapeutics Inc. (GPCR): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/GPCR"><img src="https://stoquant.com/badge/GPCR.svg" alt="Structure Therapeutics Inc. (GPCR) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.